All Episodes

Jun 25, 2026 | Ionis Tryngolza FDA Label Expansion Hits Commercial Inflection

Jun 24, 2026 | FDA Approves Gilead's Trodelvy for Front-Line TNBC; Lilly's $1.9B Abbisko Deal

Jun 23, 2026 | Pfizer Seagen ADC Fails in Lung Cancer Phase 3; CMS Settles Opzelura Classification

Jun 22, 2026 | AbbVie's $10.9B Apogee Buy Targets Dupixent; 1st Solid Tumor CAR-T Approved in China

Jun 19, 2026 | US Probes Germany Drug Pricing; Moderna Flu Vaccine Wins Unanimous FDA Panel

Jun 18, 2026 | Moderna mFlusiva Wins Unanimous VRBPAC Vote; NovoCure TRIDENT Fails in GBM

Jun 17, 2026 | UniQure AMT-130 Surges 70% on FDA Reversal; Jazz-AbCellera $4.1B TCE Deal

Jun 16, 2026 | BridgeBio BBP-418 Sweeps LGMD Phase 3; FDA Scrutinizes Moderna Flu Vaccine

Jun 15, 2026 | CMS Targets SubQ Keytruda and Opdivo Loophole; Takeda Beats Sotyktu Head-to-Head

EHA 2026 Special — Full Meeting Recap

Jun 12, 2026 | FDA Approves Merck Welireg-Keytruda for Kidney Cancer; Jazz Zepzelca Phase 3 Fails

Jun 11, 2026 | Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering

Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3

ADA 2026 Special: The full recap

The AI Vendor Draft — How Big Pharma Picked Its AI Partners | The Pharma Closeout Special Report

Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data

Jun 04, 2026 | SCOTUS Backs Hikma Skinny-Label Win on Vascepa; ADC Therapeutics Crashes 50% on Death

ASCO 2026 Special, Part 2 — ThClosing Days: Iza-bren Doubles Down in TNBC & Esophageal

ASCO 2026 Special — Comprehensive Opening Weekend: Daraxonrasib Doubles Pancreatic OS

May 31, 2026 | ASCO 2026: Revolution Medicines Pancreatic Data Called 'Unprecedented'; Ivonescimab 34% OS

May 29, 2026 | Pfizer's $10.5B Innovent Deal Extends China Licensing Wave; BMS Mezigdomide Phase 3

May 28, 2026 | GSK/Ionis Bepirovirsen Achieves 19% Functional Cure in Hepatitis B

May 20, 2026 | Pfizer's Next-Gen Pneumonia Vaccine Beats Prevnar 20; BMS Deploys Anthropic AI

May 19, 2026 | Takeda $885M Antitrust Verdict; Bimzelx Beats Skyrizi in PsA Head-to-Head

May 18, 2026 | Regeneron LAG-3 Phase 3 Failure Crashes Stock 11%; Supreme Court Cements IRA

May 15, 2026 | FDA's CDER Chief Høeg Expected to Exit; Tecentriq Wins Bladder Cancer Approval

May 14, 2026 | AstraZeneca Imfinzi Phase 3 Win in Bladder Cancer; Gene Therapy Safety Overhang

May 13, 2026 | BeOne's Beqalzi Wins FDA Approval, Breaking BCL-2 Monopoly; Takeda Cuts 4,500 Jobs

May 12, 2026 | FDA Commissioner Makary Resigns; BMS-Hengrui $15.2B 13-Asset Alliance

May 11, 2026 | CSL Flags $5B Vifor Impairment as Shares Hit Nine-Year Low

May 10, 2026 | Vyvgart Wins Broadest gMG Label; Merck Closes $6.7B Terns Deal

May 08, 2026 | Trump Plans to Fire FDA Commissioner Makary; Leqembi SC Delayed to August

May 07, 2026 | Angelini's $4.1B Catalyst Buyout; Atara Surges 40% on FDA Path Forward; Roche Acquires PathAI

May 06, 2026 | Bayer Acquires Perfuse for $2.45B in Ophthalmology; Novo Wegovy Pill Posts $355M Q1

May 05, 2026 | Cytokinetics Cracks Non-Obstructive HCM; Pfizer's $2.3B Trillium Write-Off

May 04, 2026 | SCOTUS Restores Mifepristone Mail Access; First PROTAC Drug Wins FDA Approval

May 03, 2026 | UCB's $2.2B Candid Therapeutics Deal; FDA Moves to Withdraw Tavneos

May 01, 2026 | FDA Approves First PROTAC Drug Veppanu; Pharma M&A Hits $84B in Q1; Truqap Clears ODAC 7-1

Apr 28, 2026 | Erasca Crashes 48% on Patient Death; Lilly's $2.3B Ajax Deal

Apr 27, 2026 | Sun Pharma just wrote an eleven-point-seven-five billion dollar check to acquire Organon

Apr 24, 2026 | Foundayo Trails Oral Wegovy 5-to-1 in Week 2; Inhibrx Draws $6.7B

Apr 23, 2026 | Regeneron's Otarmeni Approved as First Gene Therapy for Hearing Loss

Apr 21, 2026 | Merck Welireg Fails First-Line Kidney Cancer; Lilly's $7B Kelonia CAR-T

Apr 20, 2026 | Lilly's $7B Kelonia In Vivo CAR-T Bet; TIGIT Fails Again at Gilead-Arcus

Apr 19, 2026 | Allogene's Off-the-Shelf CAR-T Clears Futility Bar; Kailera Prices $625M IPO

Apr 16, 2026 | Lilly Foundayo Clears Heart Safety for Diabetes Filing; Cochrane Calls Amyloid Drugs 'Trivial'

Apr 15, 2026 | J&J Q1 Earnings Beat on Tremfya Growth; Revolution Medicines $2B Raise

Apr 14, 2026 | Daraxonrasib Nearly Doubles Pancreatic Cancer Survival; Neurocrine-Soleno $2.9B Deal

Apr 12, 2026 | FDA Rejects Replimune RP1 Again; Sun Pharma's $12B Organon Bid; Amgen TEPEZZA Subcutaneous Win

Apr 09, 2026 | Lilly Launches Oral GLP-1 Foundayo; Gilead's $3.15B Tubulis ADC Acquisition

Apr 07, 2026 | Pharma Tariffs Hit 100% with Major Loopholes; Gilead's $3.15B Tubulis ADC Deal

Apr 06, 2026 | Gilead's $3.15B Tubulis ADC Deal; Neurocrine's $2.9B Prader-Willi Bet

Apr 05, 2026 | Lilly Foundayo vs Novo Oral Wegovy Launch War; Trump Signs 100% Pharma Tariff

Apr 03, 2026 | Trump's 100% Drug Tariffs Reshape Pharma; $25.5B M&A Spree

Apr 02, 2026 | Trump's 100% Drug Tariff Splits Pharma; Lilly Foundayo Approved

Apr 01, 2026 | FDA Approves Lilly's Foundayo Oral Obesity Pill; Immunovant Batoclimab Fails Phase 3 TED Trials

Mar 31, 2026 | Lilly's $7.8B Centessa Deal; Biogen Buys Apellis for $5.6B; FDA Flags Tavneos Deaths | Mar 31, 2026

Mar 30, 2026 | Tyvaso's Second Phase 3 Win in IPF; Viridian Crashes 38% on TED Data

Mar 29, 2026 | Lilly's $2.75B AI Drug Deal with Insilico; Oral Psoriasis Data Reshapes Derm at AAD 2026

Mar 27, 2026 | Novo Nordisk's Once-Weekly Insulin Awiqli Wins FDA Approval; $15B+ in Pharma Deals

Mar 26, 2026 | Wave Crashes 58% on Obesity Data Miss; CVC Bids $12.6B for Recordati

Mar 25, 2026 | Merck's $6.7B Terns Acquisition for CML Drug TERN-701

Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...

Mar 23, 2026 | Apogee Eczema Data Sends Stock Up 20%; Gilead Nears $2B Ouro Medicines Deal

Mar 22, 2026 | Abbott's $21B Exact Sciences Deal Closes; Wegovy HD Approved, Orforglipron Delayed

Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast Cancer; Opdivo Approved for Hodgkin Lymphoma

Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days

Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce

Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%

Mar 16, 2026 | Structure Therapeutics Oral GLP-1 Data Rivals Orforglipron; BioMarin Halts Voxzogo Studies

Mar 15, 2026 | Immutep LAG-3 Phase 3 Failure Crashes Stock 88%; Ultragenyx Gene Therapy Hits OTc

Mar 13, 2026 | GSK Arexvy Expands to At-Risk Adults 18-49; Novartis Cosentyx Pediatric HS Approval

Mar 12, 2026 | Ultragenyx Gene Therapy Hits Phase 3 Endpoint; Lilly's $3B China Bet; LAG-3 Oncology Setback

The AI Reckoning — Episode 4: Who Wins

Mar 11, 2026 | Vertex Kidney Drug Hits Phase 3; Lilly's $3B China Expansion; UCB Bimzelx Beats Skyrizi

Mar 10, 2026 | BioNTech's co-founders just walked away

Mar 09, 2026 | Novo Nordisk Partners with Hims on GLP-1 Distribution; BMS Wins Sotyktu PsA Approval

The AI Reckoning — Episode 3: The Agentic Enterprise

Weekend Round Up March 08, 2026: Gilead's $7.8B CAR-T Bet; Servier Acquires Day One for $2.5B

Mar 06, 2026 | FDA not convinced AMT-130 works; Moderna +14% on melanoma data; Servier’s $2.5B Day One bet

Mar 5, 2026 | Theravance Phase 3 CYPRESS Failure Triggers 50% Workforce Cut, Science CoRaises $230M for Retinal BCI + Sotyktu PsA PDUFA Tomorrow

Mar 4, 2026 | Moderna’s $2.25B LNP Patent Settlement, FDA Fires 30 GLP-1 Compounding Warning Letters + Sotyktu PsA PDUFA Friday

Special Series| AI Reckoning Ep 2: From Molecule to Market — 173 AI Drugs in Trials, But Phase 2 Data Tells a Different Story

Mar 3, 2026 | Novo’s $506M Oral GLP-1 Manufacturing Bet, Sotyktu PsA PDUFA Friday, Orforglipron Race Begins

Mar 2, 2026 | Gilead’s $7.8B CAR-T Bet, YUVIWEL Approved, PADCEV-Keytruda Resets Bladder Cancer

Mar 1, 2026 | CagriSema Week of Reckoning: Analysts Revise, Novo Regroups | YUVIWEL Approved + PRV Voucher | Weekend Edition

Feb 27, 2026 | CagriSema's New Story After REDEFINE 4, GSK's $950M Activin Bet, Lilly Wins ACHIEVE-3

Special Series| AI Reckoning Ep 1: The Reckoning — 5% of Pharma Has AI Advantage, 95% Still Running Pilots